TY - JOUR KW - Bacterial Vaccines KW - Drug Therapy, Combination KW - Follow-Up Studies KW - Humans KW - Immunotherapy, Active KW - Leprostatic Agents KW - Leprosy, Borderline KW - Leprosy, lepromatous KW - Nontuberculous Mycobacteria KW - Skin KW - Treatment Outcome AU - Zaheer S A AU - Mukherjee R AU - Ramkumar B AU - Misra R S AU - Sharma A K AU - Kar H K AU - Kaur H AU - Nair S AU - Mukherjee A AU - Talwar G P AB -
Immunotherapy with Mycobacterium w vaccine was attempted in patients with borderline-borderline, borderline lepromatous (BL), or lepromatous leprosy (LL) to determine whether immunization can hasten recovery and reduce treatment time by invigorating cell-mediated immunity. Mycobacterium w, a nonpathogenic, rapidly growing, atypical mycobacterium, shares a number of common B and T cell determinants with Mycobacterium leprae and Mycobacterium tuberculosis. Patients receiving the vaccine had rapid clinical improvement and accelerated bacteriologic clearance. After treatment with vaccine for 2 years, 13 of 31 BL and LL patients were bacteriologically negative as were 5 of 25 controls. Vaccinated patients had one of two distinct histologic features, either an upgrading in the disease spectrum or complete clearance of granuloma. Some 80% of lepromin conversions were in BL and LL patients who received vaccine versus none and 14.3% of BL and LL controls, respectively. Thirteen of 17 vaccinated LL patients were released from treatment after 2 years in contrast to 2 of 15 controls.
BT - The Journal of infectious diseases C1 - http://www.ncbi.nlm.nih.gov/pubmed/8421173?dopt=Abstract DA - 1993 Feb DO - 10.1093/infdis/167.2.401 IS - 2 J2 - J. Infect. Dis. LA - eng N2 -Immunotherapy with Mycobacterium w vaccine was attempted in patients with borderline-borderline, borderline lepromatous (BL), or lepromatous leprosy (LL) to determine whether immunization can hasten recovery and reduce treatment time by invigorating cell-mediated immunity. Mycobacterium w, a nonpathogenic, rapidly growing, atypical mycobacterium, shares a number of common B and T cell determinants with Mycobacterium leprae and Mycobacterium tuberculosis. Patients receiving the vaccine had rapid clinical improvement and accelerated bacteriologic clearance. After treatment with vaccine for 2 years, 13 of 31 BL and LL patients were bacteriologically negative as were 5 of 25 controls. Vaccinated patients had one of two distinct histologic features, either an upgrading in the disease spectrum or complete clearance of granuloma. Some 80% of lepromin conversions were in BL and LL patients who received vaccine versus none and 14.3% of BL and LL controls, respectively. Thirteen of 17 vaccinated LL patients were released from treatment after 2 years in contrast to 2 of 15 controls.
PY - 1993 SP - 401 EP - 10 T2 - The Journal of infectious diseases TI - Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. VL - 167 SN - 0022-1899 ER -